Cognitive · Investigational
NAP (Davunetide)
No lawful US pathway
01 · Overview
NAP, also known as davunetide, is an eight-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). In preclinical studies it promoted microtubule stability and reduced tau phosphorylation (PMID 24873720), which led to its testing in tau-related diseases.
Intranasal delivery was pursued to achieve central nervous system access while minimizing systemic exposure.
02 · Research summary & key findings
In a 12-week randomized trial in 144 people with amnestic mild cognitive impairment, intranasal davunetide was safe but did not significantly improve the composite memory score, with signals on two individual tests (PMID 23594991). A randomized phase 2/3 trial in 313 patients with progressive supranuclear palsy, published in Lancet Neurology in 2014, found no difference from placebo on either primary endpoint over 52 weeks and concluded davunetide is not an effective treatment for the disease (PMID 24873720). Later post hoc analyses have suggested sex-specific effects (PMID 39358355), but these require confirmation.
03 · Regulatory status
NAP (Davunetide) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
NAP (Davunetide) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
NAP (Davunetide) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intranasal
References
- [1]A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Dement Geriatr Cogn Disord, 2013. PMID 23594991
- [2]Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Lancet Neurol, 2014. PMID 24873720
- [3]Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease Transl Psychiatry, 2024. PMID 39358355
Primary literature
- PubMed: "NAP"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "NAP"
Registered interventional and observational studies, including status and phase.
- PubChem: "NAP"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.